Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
07/05/2026 13:33
May 7 (Reuters) - Oragenics Inc OGEN.A: ORAGENICS SIGNS LETTER OF INTENT TO LICENSE CARDIODIALYSIS™ TECHNOLOGY FROM SIGYN THERAPEUTICS TO TARGET TBI-INDUCED SYSTEMIC INFLAMMATION ORAGENICS INC - TO RECEIVE EXCLUSIVE LICENSE FOR CARDIODIALYSIS FOR TBI AND NEURODEGENERATIVE DISEASES ORAGENICS INC - TO PAY 3% ROYALTY ON REVENUE FROM SALES OF LICENSED TECHNOLOGY FOR SIX YEARS AFTER FDA CLEARANCE ORAGENICS INC - TO ISSUE 3.25 MILLION RESTRICTED PREFERRED SHARES TO SIGYN, CONVERTIBLE ONE-TO-ONE Source text: ID:nGNX8tYPnn Further company coverage: OGEN.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing